Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noex vs. Budecort Aqua for Allergic Rhinitis
NCT02972866Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Jun 2016
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of budesonide in allergic rhinitis (AR) (2 arms), sponsored by Eurofarma. Primary endpoint: Demonstrate non inferiority of Noex comparable with referral product Budecort Aqua in the treatment of rinithis moderate to severe during 4 weeks of treatment at 28 days. Planned start Jun 2016; status: withdrawn.
02
Drugs
budesonide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02972866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972866.